Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Chubb
Moodys
Express Scripts
McKesson
Harvard Business School
Queensland Health
Chinese Patent Office
Cantor Fitzgerald

Generated: September 22, 2018

DrugPatentWatch Database Preview

Taro Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TARO PHARM, and when can generic versions of TARO PHARM drugs launch?

TARO PHARM has sixty-two approved drugs.

There are six US patents protecting TARO PHARM drugs. There are two tentative approvals on TARO PHARM drugs.

Summary for Taro Pharm
US Patents:6
Tradenames:48
Ingredients:44
NDAs:62
Patent Litigation for Taro Pharm: See patent lawsuits for Taro Pharm

Drugs and US Patents for Taro Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharm Inds CICLOPIROX ciclopirox SOLUTION;TOPICAL 078144-001 Sep 18, 2007 AT RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Taro Pharm CIPROFLOXACIN HYDROCHLORIDE ciprofloxacin hydrochloride TABLET;ORAL 076912-002 Oct 6, 2004 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Taro Pharm NORTRIPTYLINE HYDROCHLORIDE nortriptyline hydrochloride CAPSULE;ORAL 075520-003 May 8, 2000 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Taro Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taro Pharms PLIAGLIS lidocaine; tetracaine CREAM;TOPICAL 021717-001 Jun 29, 2006 5,919,479 ➤ Try a Free Trial
Taro Pharms TOPICORT desoximetasone SPRAY;TOPICAL 204141-001 Apr 11, 2013 5,990,100 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TARO PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Lotion 0.5% ➤ Subscribe 2011-03-16
➤ Subscribe Topical Spray 0.25% ➤ Subscribe 2013-12-18

Supplementary Protection Certificates for Taro Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
172 Luxembourg ➤ Try a Free Trial PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
C/GB08/005 United Kingdom ➤ Try a Free Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
C0067 France ➤ Try a Free Trial PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Argus Health
Farmers Insurance
AstraZeneca
Moodys
Queensland Health
Federal Trade Commission
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.